Literature DB >> 11087768

The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease.

P Tiraboschi1, L A Hansen, M Alford, E Masliah, L J Thal, J Corey-Bloom.   

Abstract

OBJECTIVE: To determine the timing of cholinergic loss and reduction of synapses in AD.
BACKGROUND: Decrements in neocortical synapses and cholinergic function occur in AD and correlate with cognitive decline. However, how early in the disease process these changes appear remains unclear.
METHODS: An autopsy series of 89 demented patients with pathologically confirmed AD (National Institute on Aging and Consortium to Establish a Registry for Alzheimer's Disease criteria) and 18 normal control subjects (NC). The AD cases were stratified according to their last Mini-Mental State Examination (MMSE) score prior to death as mild (MMSE = 20; n = 14), moderate (MMSE = 10 to 19; n = 20), severe (MMSE = 1 to 9; n = 29), and very severe (MMSE = 0; n = 26). Midfrontal (MF) synapse density was assessed by dot-immunobinding assay for synaptophysin (Syn), and MF choline acetyltransferase (ChAT) activity was determined using standard protocols.
RESULTS: Compared with those in NC, neither Syn nor ChAT was appreciably reduced in patients with mild AD at death. Decline of ChAT was significant only in AD patients who died in the late stages of the disease and was maximal in those who had more severely deteriorated. In contrast, decline of Syn was significant and almost maximal in patients in intermediate or moderate stages. Consequently, the last MMSE score prior to death correlated more strongly with ChAT than Syn when the AD cohort included more impaired patients (r = 0.46 versus 0.40). The reverse occurred when only less impaired patients (MMSE = 10) were included in the analyses (r = 0.28 versus 0.64). There was only a modest correlation between Syn and ChAT activity.
CONCLUSIONS: The results imply an asynchronous pattern of decline of synapses and cholinergic activity, with Syn loss preceding ChAT decrements. However, neither MF synapse reduction nor cholinergic dysfunction appears to be an early event in AD.

Entities:  

Mesh:

Year:  2000        PMID: 11087768     DOI: 10.1212/wnl.55.9.1278

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons.

Authors:  B L Kelly; A Ferreira
Journal:  Neuroscience       Date:  2007-05-17       Impact factor: 3.590

2.  Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease.

Authors:  Michel Grothe; Helmut Heinsen; Stefan J Teipel
Journal:  Biol Psychiatry       Date:  2011-08-04       Impact factor: 13.382

Review 3.  Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.

Authors:  S Chatterjee; S E Bartlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

4.  Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1-40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems.

Authors:  Wagner C Martins; Vanessa Valgas dos Santos; Alessandra Antunes dos Santos; Samuel Vandresen-Filho; Tharine A Dal-Cim; Karen A de Oliveira; Claudia B N Mendes-de-Aguiar; Marcelo Farina; Rui Daniel Prediger; Giordano Gubert Viola; Carla I Tasca
Journal:  Neurotox Res       Date:  2015-04-01       Impact factor: 3.911

5.  Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease.

Authors:  Brent L Kelly; Robert Vassar; Adriana Ferreira
Journal:  J Biol Chem       Date:  2005-07-07       Impact factor: 5.157

6.  A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Carlos Spuch; Desiree Antequera; M Isabel Fernandez-Bachiller; M Isabel Rodríguez-Franco; Eva Carro
Journal:  Neurotox Res       Date:  2009-09-23       Impact factor: 3.911

Review 7.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Blueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase.

Authors:  Yuyan Zhu; Paula C Bickford; Paul Sanberg; Brian Giunta; Jun Tan
Journal:  Rejuvenation Res       Date:  2008-10       Impact factor: 4.663

Review 9.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.

Authors:  Martijn C de Wilde; Cassia R Overk; John W Sijben; Eliezer Masliah
Journal:  Alzheimers Dement       Date:  2016-01-14       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.